APR-1051 - (ACESOT-1051)

September 22, 2026: Aprea Therapeutics (NASDAQ: APRE) announced that updated interim results from the ongoing Phase 1 ACESOT-1051 first-in-human study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors have been accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona.

The presentation, titled “Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051),” will be given by Timothy A. Yap of MD Anderson in a plenary session on November 20, 2026, from 3:00-3:10 PM CET. The trial is listed as NCT06260514.

No efficacy or safety data were disclosed in the press release itself; the catalyst is the conference oral presentation of updated interim Phase 1 data. The company also stated that APR-1051 and ATRN-119 are in clinical development for solid tumor indications.